FDA feedback puts Oncolytics (ONCY) on potential accelerated colon cancer path
Rhea-AI Filing Summary
Oncolytics Biotech Inc. reported that the U.S. FDA has provided written feedback on the design of a potential pivotal Part B expansion of REO 033, a randomized study of pelareorep in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. The feedback gives what the company views as important alignment on using objective response rate and duration of response to support a potential accelerated approval pathway, with progression-free survival to support full approval. REO 033 was designed with an initial randomized Part A and a potential pivotal Part B. Part A, with 60 patients, will generate the data that inform whether to launch Part B. Based on the FDA’s feedback, Oncolytics plans to begin Part B start-up activities as soon as positive interim Part A data are available and to pursue an End-of-Phase meeting to finalize key elements of the registration program for pelareorep in colorectal cancer.
Positive
- None.
Negative
- None.
Filing Explained
The company has foregone its scheduled Type D meeting and instead intends to pursue an End-of-Phase meeting; Part B remains conditional on positive interim Part A data, so the filing changes the planned regulatory interaction rather than launching the pivotal expansion.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
REO 033 Part A size: 60 patients
Prior pelareorep exposure: over 1,200 patients
Second-line setting: second-line
+2 more
5 metrics
REO 033 Part A size
60 patients
Ongoing randomized Part A (n=60) in second-line RAS-mutant MSS metastatic colorectal cancer
Prior pelareorep exposure
over 1,200 patients
Pelareorep has been administered to over 1,200 patients across multiple clinical studies
Second-line setting
second-line
REO 033 evaluates pelareorep in second-line RAS-mutant MSS metastatic colorectal cancer
Fast Track designations
colorectal, anal, and pancreatic cancer
Pelareorep combination therapy has received Fast Track designation in these gastrointestinal cancers
Study name
REO 033
Ongoing randomized study of pelareorep with potential pivotal Part B expansion
Key Terms
accelerated approval, progression-free survival, End-of-Phase meeting, Fast Track designation, +1 more
5 terms
accelerated approval regulatory
"potential accelerated approval pathway based on objective response rate"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
progression-free survival medical
"progression-free survival serving as the basis for full approval"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
End-of-Phase meeting regulatory
"suggested that the Company hold an End-of-Phase meeting"
A meeting between a drug or medical-device developer and a regulator that happens after a development phase to review results, resolve questions, and agree on what’s needed for the next stage. It matters to investors because the meeting can shorten uncertainty about whether a program can move forward, change the size or cost of future studies, and therefore affect timelines, development risk and the value of a program—think of it as a formal checkpoint that can speed up or slow down the project.
Fast Track designation regulatory
"Pelareorep combination therapy has received Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
microsatellite stable medical
"second-line RAS-mutant, microsatellite stable metastatic colorectal cancer"
Microsatellite stable describes a tumor whose short, repeating DNA sequences (microsatellites) show few or no errors, meaning the cancer’s internal “spell-check” system is largely intact. For investors, this matters because microsatellite stability is a biomarker that helps predict how likely a tumor is to respond to certain therapies and clinical trials, affecting drug development prospects, regulatory decisions, and the size of the potential patient market.
FAQ
What did Oncolytics Biotech (ONCY) announce regarding FDA feedback on REO 033?
Oncolytics Biotech announced written FDA feedback providing alignment on a potential pivotal Part B expansion of the REO 033 study in second-line RAS-mutant MSS metastatic colorectal cancer, including a potential accelerated approval pathway using response-based endpoints.
How could REO 033 support potential approval of pelareorep for colorectal cancer?
The proposed pathway contemplates accelerated approval based on objective response rate and duration of response, with progression-free survival serving as the basis for full approval, subject to supportive Part A data and further regulatory agreement.
What is the current design and size of Part A in the REO 033 study for ONCY?
Part A of REO 033 is an ongoing randomized clinical trial with 60 patients (n=60), evaluating pelareorep plus FOLFIRI and bevacizumab versus FOLFIRI and bevacizumab alone in second-line RAS-mutant, MSS metastatic colorectal cancer.
How does Oncolytics Biotech plan to transition from Part A to Part B of REO 033?
Oncolytics plans to launch Part B start-up activities as soon as positive interim Part A data are available, aiming to minimize time between supportive Part A results and initiation of a potential pivotal Part B expansion.
What prior clinical experience with pelareorep does Oncolytics Biotech (ONCY) highlight?
Oncolytics notes pelareorep has been administered to over 1,200 patients and has shown encouraging results in metastatic colorectal, pancreatic, anal, and breast cancer studies, with Fast Track designation in colorectal, anal, and pancreatic cancer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
